The director of Mexican pharmaceutical industry association CANIFARMA, Rafael Gual Cosío, speaks out about the current contradictions plaguing Mexico’s pharma sector. Gual Cosío highlights the fact that market growth and revenue increases are being seen despite regulatory backlog and medicine shortages due to inefficient handling of the public system. He also argues that the reorganisation of Mexico’s public health insurance system, Seguro Popular, was hindered by a lack of planning and that the country’s pandemic response was “terrible,” while remaining optimistic about the future.
The Mexican industry is going through a period of uncertainty, but I believe we will be in a better position in three or four years. Companies are performing well despite the chaos
